Beijing Avistone Pharmaceuticals Biotechnology Co. Ltd. has disclosed spiro/bridged ring compounds acting as HER2 (erbB2) (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla mutant]) inhibitors reported to be useful for the treatment of atherosclerosis, cancer and pulmonary fibrosis.